Literature DB >> 2506279

Induction of multinucleated giant cell formation from human blood-derived monocytes by phorbol myristate acetate in in vitro culture.

N F Hassan1, N Kamani, M M Meszaros, S D Douglas.   

Abstract

Multinucleated giant cells (MGC) of mononuclear phagocyte origin occur in different tissues in various inflammatory states and pathological conditions. Although MGC are believed to be derived from monocyte-derived macrophages by fusion, their mechanism of formation is not known. In this study, we investigated the role of PMA, a protein kinase C activator, in the induction and formation of MGC from blood monocyte-derived macrophages in in vitro culture. The addition of PMA (1 x 10(-9) to 8 x 10(-8) M) to 3-wk-old cultures of blood-derived monocytes induces cell fusion with a 30% to 80% fusion rate. Moreover, IFN-gamma-treated blood-derived monocyte cultures showed an additional enhancement of fusion rate with the addition of PMA. 1(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride, a protein kinase inhibitor, inhibited the formation of macrophage-derived giant cells when added before phorbol ester and IFN-gamma. These findings suggest that protein kinase C may play an important role in the formation of macrophage-derived MGC.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2506279

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  B-1 cells are pivotal for in vivo inflammatory giant cell formation.

Authors:  Cristina Stewart Bittencourt Bogsan; Ronni Rômulo Novaes e Brito; Maiko da Cruz Palos; Renato Arruda Mortara; Sandro Rogério Almeida; José Daniel Lopes; Mario Mariano
Journal:  Int J Exp Pathol       Date:  2005-08       Impact factor: 1.925

2.  Effect of hematopoietic growth factors on human blood monocytes/macrophages in in vitro culture.

Authors:  N F Hassan; J Chehimi; W Z Ho; D E Campbell; S D Douglas
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

3.  Paradoxical stimulation and inhibition by protein kinase C modulating agents of lipopolysaccharide evoked production of tumour necrosis factor in human monocytes.

Authors:  R G Coffey; L L Weakland; V A Alberts
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

4.  Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders.

Authors:  E Brouwer; J W Tervaert; G Horst; M G Huitema; M van der Giessen; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

5.  Foreign body-type multinucleated giant cell formation is potently induced by alpha-tocopherol and prevented by the diacylglycerol kinase inhibitor R59022.

Authors:  Amy K McNally; James M Anderson
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

6.  Interleukin-4-induced macrophage fusion is prevented by inhibitors of mannose receptor activity.

Authors:  A K McNally; K M DeFife; J M Anderson
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

7.  Foreign body-type multinucleated giant cell formation requires protein kinase C beta, delta, and zeta.

Authors:  Amy K McNally; Sarah R Macewan; James M Anderson
Journal:  Exp Mol Pathol       Date:  2007-11-09       Impact factor: 3.362

8.  Inability of normal human intestinal macrophages to form multinucleated giant cells in response to cytokines.

Authors:  S Fais; F Pallone
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

9.  The method of surface PEGylation influences leukocyte adhesion and activation.

Authors:  Z Ademovic; B Holst; R A Kahn; I Jørring; T Brevig; J Wei; X Hou; B Winter-Jensen; P Kingshott
Journal:  J Mater Sci Mater Med       Date:  2006-03       Impact factor: 3.896

10.  Induction of multinucleated giant cells from rheumatoid arthritis (RA) synovial adherent cells by anti-DR antibody.

Authors:  T Matsuyama; N Nakashima; T Matsuda; H Nakamura; S Uchida; T Abe
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.